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Abstract
Myosin binding protein-C (MyBP-C) exists in three major isoforms: slow skeletal, fast skeletal, and cardiac. While
cardiac MyBP-C (cMyBP-C) expression is restricted to the heart in the adult, it is transiently expressed in neonatal
stages of some skeletal muscles. However, it is unclear whether this expression is necessary for the proper
development and function of skeletal muscle. Our aim was to determine whether the absence of cMyBP-C alters the
structure, function, or MyBP-C isoform expression in adult skeletal muscle using a cMyBP-C null mouse model
(cMyBP-C(t/t)). Slow MyBP-C was expressed in both slow and fast skeletal muscles, whereas fast MyBP-C was
mostly restricted to fast skeletal muscles. Expression of these isoforms was unaffected in skeletal muscle from
cMyBP-C(t/t) mice. Slow and fast skeletal muscles in cMyBP-C(t/t) mice showed no histological or ultrastructural
changes in comparison to the wild-type control. In addition, slow muscle twitch, tetanus tension, and susceptibility to
injury were all similar to the wild-type controls. Interestingly, fMyBP-C expression was significantly increased in the
cMyBP-C(t/t) hearts undergoing severe dilated cardiomyopathy, though this does not seem to prevent dysfunction.
Additionally, expression of both slow and fast isoforms was increased in myopathic skeletal muscles. Our data
demonstrate that i) MyBP-C isoforms are differentially regulated in both cardiac and skeletal muscles, ii) cMyBP-C is
dispensable for the development of skeletal muscle with no functional or structural consequences in the adult
myocyte, and iii) skeletal isoforms can transcomplement in the heart in the absence of cMyBP-C.
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Introduction
Myosin binding protein-C (MyBP-C) is a modular thick
filament protein belonging to the intracellular immunoglobulin
(Ig) and fibronectin (Fn) superfamily (Figure 1). It is found in
vertebrate cardiac and skeletal muscle and has both regulatory
and structural functions [1,2]. It is localized in 7-9 axial stripes,
43 nm apart, in the middle one-third (the “C zone”) of each half
A-band [3]. The localization and arrangement of these stripes
are highly conserved among different MyBP-C isoforms [4].
MyBP-C can bind myosin at two sites; the N-terminal region
binding to S2 [5] and to the regulatory light chain [6], and the C-
terminus binding to light meromyosin [7]. MyBP-C can also
bind to actin [4] [8], as well as to other thick filament proteins,
such as titin [9]. There are 3 isoforms of MyBP-C, each
encoded by a distinct gene: fast-skeletal, slow-skeletal, and
cardiac [10–13]. The cardiac isoform (cMyBP-C) differs from
the skeletal isoforms in that cMyBP-C has an extra Ig domain
at the N-terminus (C0), four phosphorylation sites within a
MyBP-C specific domain known as the M-domain, and a 28
residue insert in the C5 Ig module [14] (Figure 1). The two
skeletal isoforms of MyBP-C expressed in mature skeletal
muscles are slow MyBP-C (sMyBP-C) and fast MyBP-C
(fMyBP-C), encoded by the MYBPC1 and MYBPC2 genes,
respectively (Table 1). MYBPC1 is expressed in both slow and
fast skeletal muscles, whereas MYBPC2 is expressed only in
fast skeletal muscle [12]. The cMyBP-C gene (MYBPC3) is
predominantly expressed in cardiac muscle [15,16]. Mutations
in MyBP-C lead to myopathy in both skeletal and cardiac
muscles. MYBPC1 mutations cause distal arthrogryposis type
1 [17], while mutations in MYBPC3 are associated with the
development of hypertrophic cardiomyopathy (HCM) [18,19].
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Mouse models lacking cMyBP-C exhibit pronounced
cardiomyopathies, including HCM [20] and dilated
cardiomyopathy (DCM) [21].
While skeletal and cardiac MyBP-C are expressed primarily
in their corresponding tissues, expression of skeletal MyBP-C
in cardiac tissue and of cMyBP-C in skeletal tissues can also
occur. In addition to its expression in skeletal muscles, sMyBP-
C is also expressed in the right atrium and the interatrial
septum of the heart [22]. Likewise, during avian
embryogenesis, the cMyBP-C gene, MYBPC3, is expressed in
Figure 1.  Schematic diagram of striated muscle sarcomere and the three main isoforms of MyBP-C.  (A) The bulk of MyBP-
C is oriented perpendicularly to the long axis of the myosin filaments and is restricted to the C-zone in the central 1/3 of each half A-
band (vertical arrows). Titin (dashed lines) is a giant protein that spans the length of the half-sarcomere. MyBP-C is restricted to the
C-zone of the A-band and connects both thick and thin filaments [1]. (B) The three main isoforms of MyBP-C: a cardiac form
(cMyBP-C) and two skeletal isoforms, slow and fast (sMyBP-C and fMyBP-C, respectively). MyBP-C isoforms each have a proline–
alanine (P/A)-rich region towards the N-terminus, three fibronectin type III domains (hexagons), and seven immunoglobulin domains
(circles). The cardiac isoform has an additional immunoglobulin domain, C0, at the N-terminus, phosphorylation motifs in the M
domain (red vertical band), and a twenty-eight residue cardiac-specific insert in the C5 immunoglobulin domain (red vertical band).
The cardiac and fast skeletal isoforms share a conserved ‘linker’ between the C4 and C5 domains (dark thick band). Distinctions
between the different isoforms are highlighted.
doi: 10.1371/journal.pone.0069671.g001
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skeletal muscle in addition to its expression in cardiac muscle
[23]. This skeletal expression of cMyBP-C in birds occurs early
in embryonic development, followed by later expression of
skeletal isoforms [24]. Since it is formed at the same time as
myosin and titin, cMyBP-C is hypothesized to be necessary for
the formation of skeletal sarcomeres during myofibrillogenesis.
These studies suggest that i) cMyBP-C is necessary for
skeletal muscle development, and ii) its ablation could
therefore alter adult skeletal muscle structure and function.
While cMyBP-C expression in developing avian skeletal muscle
is well established and has also been observed in amphibians
[25], comparable evidence for cMyBP-C in developing
mammalian skeletal muscle has been lacking [15,16].
Nevertheless, two intriguing observations suggest that this
possibility should not be discounted. Mutations in MYBPC3,
normally associated with the development of HCM [18,19],
have also been demonstrated to cause skeletal myopathy,
apparently due to expression of mutated cMyBP-C in the
skeletal muscle [26]. Furthermore, in studies of human skeletal
myoblast-to-myotube transitions, cMyBP-C transcript was
present [27]. However, cMyBP-C protein was not detected by
immunohistochemistry, which is not very sensitive for detecting
proteins.
These observations have prompted us to further explore the
possible significance of cMyBP-C in developing skeletal muscle
of mammals, particularly whether the absence of cMyBP-C
affects normal skeletal muscle structure and function [16]. We
have assessed the expression of MyBP-C isoforms, the
structure of the skeletal muscles, and the functional
characteristics of slow (soleus) and fast (extensor digitorum
longus, EDL) skeletal muscles in the cMyBP-C null mouse
model (t/t) ) [21] to test whether i) cMyBP-C is necessary for
Table 1. Summary of differences in gene location,
expression, and known associated myopathies among the
three major isoforms of MyBP-C.
 sMyBP-C fMyBP-C cMyBP-C
Gene symbol MYBPC1 MYBPC2 MYBPC3
Chromosome
location (human) 12 19 11
Chromosome
location (mouse) 10 7 2
mRNA size
(mouse) 3941 base pairs 3610 base pairs 4224 base pairs
Protein length
(mouse) 1127 amino acids
1136 amino
acids 1270 amino acids
Expression
Profile(adult tissue)    
Heart Yes No Yes
Skeletal Muscle Yes Yes No
Diseases
Distal
arthrogryposis
type I
No skeletal
myopathies
currently
associated
Hypertrophic
cardiomyopathy;
dilated
cardiomyopathy;
skeletal myopathy
Database reference: www.ncbi.nlm.nih.gov
normal adult skeletal muscle structure, ii) DCM-induced
myopathy leads to alteration in MyBPC expression, and iii)
transcomplementation of skeletal MyBP-C isoforms
compensates for the absence of cMyBP-C in the heart,
compared to the wild-type (WT) control mice. Our data show
that absence of cMyBP-C does not induce significant changes
in isoform expression in skeletal muscle, nor does it produce
any significant structural or functional deficit in skeletal muscle,
indicating that cMyBP-C is dispensable for normal muscle
development. However, there is an increase in fMyBP-C, but
not sMyBP-C, in the heart.
Results
MyBP-C isoform expression patterns in adult striated
muscle
To determine the differential expression of MyBP-C isoforms
in adult muscle, extracts of cardiac and skeletal tissue from (t/t)
and WT mice were probed by Western blotting for the slow,
fast, and cardiac isoforms of MyBP-C, using antibodies known
to be specific for these isoforms. cMyBP-C was not detected in
either slow or fast skeletal muscle tissues (Figure 2A–C),
confirming that cMyBP-C expression is restricted to the adult
heart. Strong expression of sMyBP-C was determined to be
present in both the soleus and EDL. Prominent expression of
fMyBP-C was detected in the EDL of both (t/t) and WT mice,
but detectable quantities were also found in soleus muscles of
(t/t) and WT mice. In contrast with studies indicating that
sMyBP-C is natively expressed in the right atria and interatrial
septum of other species [22], we did not detect sMyBP-C in
whole heart homogenates of our mice. Strikingly, fMyBP-C
expression level was significantly increased in the (t/t) hearts,
compared to the WT ventricles (Figure 2B, EF & G). In order to
increase the anti-fMyBP-C antibody sensitivity, samples were
reanalyzed without skeletal muscle controls for fMyBP-C
(Figure 2F). As expected, fMyBP-C expression was markedly
increased in the (t/t) hearts, compared to the WT hearts, which
displayed no fMyBP-C expression (Figure 2G). These data
suggest that in adults, cMyBP-C is exclusive to the heart and
not expressed in WT and DCM-induced HF skeletal muscles.
Dystrophic skeletal muscles of mdx mice (a model of human
Duchenne muscular dystrophy) display significant
degeneration-regeneration cycles that are reminiscent of
developing myocytes. To assess whether cMyBP-C might be
expressed in skeletal muscles as part of these cycles,
dystrophic skeletal muscles of mdx mice were analyzed. EDL
fast muscle samples were collected from 6-month old WT and
mdx mice and analyzed for the expression of sMyBP-C,
fMyBP-C, and cMyBP-C by Western blot analysis. Results
showed that cMyBP-C was not expressed in the skeletal
myopathy muscles (Figure 3). In contrast, sMyBP-C and
fMyBP-C were both significantly increased in the mdx muscles.
Taken together, these data suggest that in the adult 1) cMyBP-
C is exclusively expressed in cardiac, but not skeletal, tissue of
either WT or mdx mice, 2) fMyBP-C expression is increased in
the absence of cMyBP-C in (t/t) mouse hearts, and 3)
increased expression of sMyBP-C or fMyBP-C could be a
marker of skeletal myopathy. Furthermore, our data confirm
MYBPC3 Plays No Role in Skeletal Muscle
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Figure 2.  MyBP-C isoforms are differentially expressed in cardiac and skeletal tissue.  Ten µg of total proteins were resolved
on 4-15% SDS-PAGE and stained with Coomassie Brilliant Blue (A). Expression levels of cardiac, slow skeletal and fast skeletal
MyBP-C in (t/t) and WT mice were determined in heart (h), soleus (s) and EDL (e) muscles by Western blot analysis with respective
antibodies (B). Representative Western blot shows that the presence of cardiac isoform of MyBP-C (cMyBP-C) is exclusive to
ventricular muscle of WT mice (C), but completely absent in the (t/t) mouse hearts. sMyBP-C was significantly expressed both in the
soleus muscle and EDL muscle (D). Conversely, fMyBP-C was mainly detected in EDL muscle (E), but significantly increased in the
(t/t) hearts. All values were normalized to the expression of α-sarcomeric actin (MyBP-C/actin ratio) and expressed as relative
values. The summarized quantitative data were derived from n=3 with mixed gender mice (*p< 0.01 versus WT). The increased
level of fMyBP-C expression in the (t/t) hearts was reconfirmed by Western blot analysis (F) and not found in the WT hearts,
summarized in panel G (n=6, *p< 0.0001 versus WT). α-sarcomeric actin was used as a loading control.
doi: 10.1371/journal.pone.0069671.g002
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that sMyBP-C is expressed in slow and fast skeletal muscles,
while fMyBP-C is predominantly expressed only in fast skeletal
muscles.
cMyBP-C is dispensable for development of normal
adult muscle structure
To determine whether ablation of cMyBP-C in the (t/t) mice
alters sarcomere structure in skeletal muscles, electron
microscopy analyses were performed using slow (soleus) and
fast (EDL) skeletal muscles from (t/t) and WT mice. Muscles
were studied by negative staining of isolated, fixed myofibrils
and by longitudinal and transverse sectioning of fixed and
embedded specimens (Figure 4 A–C). Results showed no
apparent difference between (t/t) and WT mice in any of the
skeletal muscles tested. Soleus and EDL muscles showed
typical A-bands, I-bands, M-lines, and Z-lines in both sections
and myofibrils, with no significant difference in lengths between
Figure 3.  cMyBP-C was not expressed in myopathic
skeletal muscles. .  To determine the expression level of
MyBP-C isoforms in myopathic fast skeletal muscles, three and
six µg of total EDL muscle proteins from both WT and mdx
mice were loaded into SDS-PAGE followed by immunoblotting
using respective MyBP-C antibodies (A). The quantitative data
were summarized in panel B (n=4, *p<0.01 versus WT).
GAPDH was used as a loading control.
doi: 10.1371/journal.pone.0069671.g003
WT and (t/t) (Table 2). In the negatively stained specimens,
transverse stripes were often very prominent in the A-bands of
both (t/t) and WT muscles. The stripes most likely represent
cardiac troponin, based on their ~38 nm periodicity measured
in Fourier transforms and their appearance in the I-band in
some cases. Though MyBP-C stripes can sometimes be
visualized in myofibrils and sections, they were not apparent in
these specimens, even in the WT muscle. Therefore, we
cannot draw any conclusions about possible effects of cMyBP-
C ablation on the MyBP-C stripes in (t/t) skeletal muscles.
Transverse views of both (t/t) and WT mouse showed the
typical hexagonal lattice structure of thick and thin filaments in
the A-band (Figure 4 C). Filament diameter and degree of
ordering were similar between (t/t) and WT muscles. Other
cellular features, such as membranes and mitochondria, were
also similar between (t/t) and WT skeletal muscles. Neither
trichrome nor H&E staining revealed any differences in gross
histology or fibrosis in the skeletal muscles of WT and (t/t) mice
(Figure 4 D-E).
cMyBP-C ablation does not affect skeletal muscle
function
To determine whether absence of cMyBP-C during skeletal
muscle development and the presence of DCM-induced HF
would affect skeletal muscle function in the (t/t) mice, soleus
muscles were evaluated for twitch tension, tetanic tension, and
injury susceptibility (Figure 5). Fractional loss of twitch force
following eccentric contraction was used to estimate injury
(Table 3). Results show no difference between (t/t) and WT
mice for twitch tension measured prior to tetanus. Twitch
tension after eccentric contraction was reduced ~10% in both
groups, indicating no increased susceptibility to injury in the (t/t)
mice. Tetanus tension was highly variable and not significantly
different in either groups. Muscle stiffness (percent of change
during stretch) was modestly increased in (t/t) mice in
comparison with that of WT mice (p > 0.05, n = 8), indicating a
slight, but not statistically significant, increase in stiffness in (t/t)
mice. These data suggest that cMyBP-C ablation and presence
of DCM-induced HF has no effect on skeletal muscle function
at 6 months of age in mice.
MyBP-C isoforms have distinct promoter regions
Since each MyBP-C isoform is encoded by its own unique
gene, we hypothesized that each MyBP-C could be uniquely
regulated by tissue-specific transcription factors, which would
account for differential tissue-specific expression. We
examined putative binding sites of myocyte enhancer factor 2
(MEF2) and the GATA family of transcription factors, both of
which are important in normal cardiac and skeletal muscle
development, as well as the development of HF [28,29]. To
determine whether differential expression of MyBP-C in the
heart and skeletal muscles is mediated by unique transcription
factors, we used promoter analysis to identify all the
transcription factors in mice. Our computational promoter
analysis was done using the 4kb upstream regions for putative
binding sites of MEF2 and GATA family members, because
these are the major transcription factors that regulate cardiac
and skeletal muscle specificity. Results show that the binding
MYBPC3 Plays No Role in Skeletal Muscle
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Figure 4.  Ultrastructural and histopathological analyses show similar sarcomeric structure in (t/t) and WT soleus and EDL
skeletal muscles.  Phenotype of mouse soleus (slow) and EDL (fast) muscle myofibrils observed by negative staining (A) and thin
sectioning (B and C). The structure and organization of sarcomeres in both longitudinal section (B) and transverse section (C) are
not disrupted in either soleus or EDL in (t/t) mice. A-band length, M-line width and Z-disc width confirm electron microscopy images,
showing no significant change between (t/t) and WT mice (Table 2). I-band length variations are likely due to different lengths of the
muscle during fixation. Scale bars = 200 nm. Representative hematoxylin and eosin (D) and Masson’s trichrome (E) staining images
show no detectable changes in myofibrils or fibrosis in the (t/t) soleus muscles, compared to the WT control.
doi: 10.1371/journal.pone.0069671.g004
MYBPC3 Plays No Role in Skeletal Muscle
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sites for GATA elements are significantly enriched in MYBPC3
(70 binding sites), compared to the MYBPC1 (16 binding sites)
and MYBPC2 (7 binding sites) genes. Binding sites for MEF2
are located in both MYBPC1 (6 binding sites) and MYBPC3 (2
binding sites) genes, but absent in the MYBPC2 gene. The
MYBPC3 promoter overlaps with the last two exons and last
intron region of SFPI1, a neighboring gene about 2500 base
pairs upstream from MYBPC3 on mouse chromosome 2. The
promoter for MYBPC2 overlaps with the last exon of SPIB on
chromosome 7. Putative binding sites for TTF are found in
MYBPC2 and MYBPC3 promoters, but they are absent in the
MYBPC1 promoter. MYBPC2 has two sites within 100 base
pairs, while MYBPC3 has only one site in the 4000 base pairs
upstream region we analyzed. A few binding sites for MEF2
were present in both MYBPC1 and MYBPC3, but completely
absent in MYBPC2. These data support our analysis that
isoforms of MyBP-C are differentially expressed in both cardiac
and skeletal muscles.
Discussion
In this study, we determined whether cMyBP-C is necessary
for the proper development and function of skeletal muscle, as
appeared possible from studies of avian species and from
certain observations on mammalian skeletal muscle
[23,24,27,30]. We investigated the differential expression of
MyBP-C isoforms in cardiac and skeletal muscles in mice
lacking cMyBP-C and in dystrophic mice. Our studies confirm
that cMyBP-C is completely ablated in the (t/t) mice and is
never expressed in adult skeletal muscles of WT or myopathic
(mdx) mice, whether the tissue is slow type (soleus) and fast
type (EDL). Furthermore, we show that cMyBP-C is completely
dispensable for normal structure and function of skeletal
muscle and that fMyBP-C, while expressed in the heart in the
(t/t) mouse, does not prevent dysfunction. These data show
that transient expression of cMyBP-C in developing skeletal
Table 2. Summarized quantitative values of the sarcomere
structure.
  Soleus EDL
 (µm) t/t WT t/t WT
Myofibril A-band 1.65 ± .02 1.64 ± .01 1.62 ± .01 1.66 ± .04
 M-line 0.13 ± .001 0.12 ± .01 0.12 ± 0.01 0.12 ± .01
 Z-line 0.09 ± 0.01 0.10 ± 0.01 0.11 ± .01 0.09 ± 0.15
Section A-band 1.44 ± .03 1.48 ± .03 1.44 ± 0.03 1.49 ± .02
 M-line 0.11 ± .01 0.12 ± .01 0.13 ± .01 0.12 ± .01
 Z-line 0.09 ± .01 0.09 ± .01 0.05 ± .01 0.05 ± .01
Average length of A-band and width of M-line and Z-line in (t/t and WT muscles
determined by negative staining (Myofibril) and thin sectioning (Section).
Measurements of the electron microscopy images were averaged from
approximately 10 well-oriented sarcomeres in each case. No significant differences
were observed between the (t/t and WT mice in either the soleus or EDL muscles.
Shorter A-band lengths in the sections compared with negatively stained myofibrils
are consistent with shrinkage effects that are commonly seen during specimen
preparation for thin section electron microscopy.
muscle is not required for normal adult skeletal muscle function
and that other isoforms are not upregulated in skeletal muscle
to compensate for the lack of cMyBP-C.
Our study is in good agreement with previous reports
indicating that cMyBP-C does not transcomplement in adult
skeletal muscle [15,16,27]. In addition, (t/t) mice skeletal
muscle did not exhibit any structural nor functional
abnormalities, indicating that cMyBPC is dispensable for
normal muscle development. Studies of avian muscle have
shown that cMyBP-C expressed during embryonic skeletal
muscle development plays a critical role in myofibrillogenesis
[23,24,30]. While mammalian studies argue against a
comparable role for cMyBP-C in mammals, observations of
skeletal myopathy in an infant with a truncating MYBPC3
mutation [26], and the finding of cMyBP-C transcripts in
proliferating human skeletal mononucleated myoblasts and
myotubes [27] have suggested that this possibility should be
kept open. Our study determined that global cMyBP-C ablation
in (t/t) mice showed no structural or functional deficits in
skeletal muscles, and we confirmed that cMyBP-C is neither
expressed in normal adult skeletal muscle nor induced as a
result of skeletal myopathy in mdx mice. Thus, expression of
cMyBP-C in mammals is restricted to cardiac muscle and does
not transcomplement in skeletal muscles. cMyBP-C appears to
be dispensable for adult skeletal muscle structure and function;
early embryonic expression of cMyBP-C in myoblasts may be
ectopic [27], without any specific role in adult skeletal muscle.
Our results confirm that sMyBP-C is significantly expressed
in both slow and fast skeletal muscles, whereas fMyBP-C is
predominantly expressed only in fast skeletal muscle [27,31].
sMyBP-C is the first isoform to be expressed in both mice and
humans during skeletal muscle development, followed by
fMyBP-C in fast skeletal muscles [15,31]. Moreover, sMyBP-C
and fMyBP-C are co-expressed and co-exist in the same
muscle type and sarcomere [16,22,31,32]. Interestingly,
sMyBP-C, which is expressed in the right atrium and interatrial
septum of adult vertebrate heart [22], has four variants that are
differentially spliced and regulated in skeletal muscles [33].
However, it is unknown whether skeletal MyBP-C isoforms are
upregulated in the heart either due to absence of the cardiac
isoform or presence of HF. In the case of troponin, troponin I
and T have slow, fast, and cardiac isoforms [34,35]. The
cardiac and skeletal isoforms are expressed in both skeletal
and cardiac muscles during development, and the skeletal
isoforms are upregulated in the heart during HF [34,36],
indicating that transcomplementation occurs. Skeletal myosin
heavy chains (isoforms I, IIa, and IIx) [37] and α-skeletal actin
[38] are also expressed in the heart during the development of
HF. Urboniene et al. (2005) showed that expression of slow
skeletal troponin I in the heart improves cardiac function [39].
These studies suggest that expression of skeletal sarcomeric
protein isoforms in the heart during HF can be beneficial.
Therefore, we determined the expression of skeletal MyBP-C
isoforms in hearts that did not express cMyBP-C. We found
that fMyBP-C was significantly increased in the (t/t) mouse
hearts compared to WT. In contrast, sMyBP-C was expressed
in both (t/t) and WT hearts in atria, but not ventricles. We found
that the expression levels of both sMyBP-C and fMyBP-C
MYBPC3 Plays No Role in Skeletal Muscle
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skeletal isoforms were unaltered in (t/t) mouse skeletal muscles
compared to the WT mouse control, suggesting that ablation of
cMyBP-C does not alter skeletal isoform expression. However,
both skeletal isoforms were significantly increased in the mdx
skeletal muscles, as described previously [16]. Interestingly,
promoter analysis supports our hypothesis that MyBP-C
isoforms are differentially regulated in both cardiac and skeletal
muscles. Specifically, GATA binding sites, but not MEF2 sites,
are enriched in the MYBPC3 gene; in contrast, low abundance
of MEF2 and GATA sites are present in MYBPC1. These
studies further show that the enriched level of GATA binding
sites in MYBPC3 indicates its specific expression in cardiac
and not skeletal muscles. However, it should be noted that
these binding sites are computationally predicted and therefore
may or may not be functional [40,41]. Taken together, our
analysis demonstrates that skeletal isoforms are differentially
regulated in the heart and skeletal muscles.
Skeletal myopathies are diseases that affect skeletal
muscles, either by inherited genetic defects or concomitant with
endocrine, inflammatory, or metabolic disorders [42]. Inherited
myopathies, including periodic paralysis, muscular dystrophies,
and congenital myopathies, are caused by genetic defects that
lead to the absence of essential functional proteins or the
presence of modified proteins that cause skeletal muscular
defects. Furthermore, patients with HF often develop reduced
skeletal muscle function, manifesting itself as exercise
intolerance [43,44]; and are often at risk for developing non-
cardiac deficits, including skeletal muscle myopathies [45,46].
While some studies show that insults to the heart do not
appear to alter skeletal muscle structure and function [47],
other evidence suggests that cardiac myopathies do adversely
Figure 5.  Analysis of twitch and tetanic tension shows no differences between (t/t) and WT mice.  Skeletal muscles were
attached to a micrometer and force transducer to measure twitch and tetanus tension with mechanical stretches of varying velocities
(20, 40, and 60, 100 ML/s) for 100 ms duration (see Methods). Injury from stretch was determined from fractional loss of twitch force
prior to tetanus versus post-tetanus stimulation. Stiffness of the muscle was determined from change in force under tetanus. An
example tracing from (t/t) soleus muscle is shown here. Measurements from functional analyses of (t/t) and WT are summarized in
Table 3.
doi: 10.1371/journal.pone.0069671.g005
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affect skeletal muscle function in humans [48]. To further
understand the relationship between heart failure and skeletal
muscle function, we investigated whether DCM-induced HF in
(t/t) mice altered the ultrastructure or function of the skeletal
muscles, compared to the WT control. Despite disruption of
both structure and function in cardiac tissue in the (t/t) mice
[21], electron microscopy and histology both revealed that the
absence of cMyBP-C in (t/t) mice had no effect on the structure
or organization of myofilaments in either fast or slow skeletal
muscles. Furthermore, no functional differences were observed
in the (t/t) skeletal muscles compared to WT mice. The lack of
functional phenotype in skeletal muscle due to lack of cMyBP-
C may be in part explained by the varying etiology, severity,
and individual physiological responses to a dysfunctional heart,
i.e. some patients may develop secondary dysfunction in the
skeletal muscles while others only present symptoms specific
to the heart. Tissues from (t/t) mice did not exhibit any
statistically significant difference from WT mice in twitch
tension, tetanus, and percent of recovery after stretch.
However, percent of change during stretch was slightly
elevated in (t/t) mice, indicating that (t/t) mice may have slightly
increased skeletal muscle stiffness, in accordance with
previous data from heterozygous mice (+/t) that demonstrated
a similar trend (unpublished data). In the case of the
heterozygous mice, fibers had to be stretched to a longer total
length to reach a 2.2 µm sarcomere length compared to the
WT fibers. In the absence of structural changes in electron
micrographs or histological sections, our study cannot
determine whether the trend in increased stiffness (p<0.10) is
physiological or an artifact of the experimental setup in the (t/t)
mice. Studies indicate that the duration of stress on peripheral
tissues imposed by HF is an important factor leading to
dysfunction [45]. Chronic HF has been shown to decrease
skeletal muscle blood flow, but this is not immediately
detrimental due to compensatory mechanisms. Eventually
these mechanisms fail, especially with the introduction of
additional stressors, such as exercise or advanced age [49].
The addition of stressors was not tested in our experiments.
While it is possible that the skeletal muscle of (t/t) mice was not
sufficiently challenged, we did allow enough time for DCM to
Table 3. Summarized values of soleus muscle kinetics in
vitro.
 
Twitch Tension
(mN/mm2)
Recovery after
stretch (%)
Tetanus
(mN/mm2)
Change during
stretch (%)
(t/t) 8.2 ± 1.2 88.2 ± 9.4 113.2 ± 13.7 87.8 ± 11.3
WT 6.1 ± 1.8 92.5 ± 6.1 87.2 ± 22.6 63.4 ± 7.5#
Skeletal muscle function was determined in soleus muscles of (t/t and WT mice.
Twitch tension was measured after 3V, 7ms electrical stimulation of 0.5Hz, and
tetanus tension was measured after 3V, 100ms at 20Hz with mechanical stretches
of different velocities applied for 100ms. Twitch tensions were measured post-
tetanus, and characteristics of injury from stretch and viscoelastic stiffness were
taken from comparisons of fractional loss of twitch force and change in force with
the stretches, respectively. The modest change in tetanus during stretch reflects a
higher stiffness in the (t/t mice on the order of ~40% compared to WT (n 8 muscles
from four mice in each group (#p<0.10)).
manifest in the (t/t) mice and ample time after the development
of DCM to observe any downstream effects. Future studies will
determine whether potential structural and functional changes
in the skeletal muscle of (t/t) mice may be induced by exposing
skeletal muscle to additional stressors, such as exercise or β-
adrenergic stimulation.
In conclusion, our study demonstrates that in mice, cMyBP-C
is exclusively expressed in the heart and not skeletal muscles.
In contrast, sMyBP-C is expressed in the right atrium and the
outflow track of myocardium, and fMyBP-C is expressed in the
ventricles in the absence of cMyBP-C in the heart, such as
during DCM-induced HF. We determined that ablation of
cMyBP-C does not affect the structure and function of either
slow or fast skeletal muscles in 6-month-old mice, underscoring
its role specifically in cardiac muscles. Furthermore, lack of
cMyBP-C does not contribute to skeletal muscle dysfunction
and myopathy and that cMyBP-C is dispensable in the
development of skeletal muscle. Systematic studies using
mouse models are underway to determine whether isoform
expression during embryogenesis is affected by the absence of
cMyBP-C and whether fMyBP-C or sMyBP-C can compensate
for the cMyBP-C deficit and heart failure. Finally, it will be
important to determine whether fMyBP-C expression in the
heart has any functional role in altering cardiac contractility.
Materials and Methods
cMyBP-C(t/t) Mouse Model
Six-month-old knock-in mouse model (cMyBP-C(t/t) or (t/t)), in
which a homozygous mutation in MYBPC3 causes a C’-
modified cMyBP-C that does not incorporate into sarcomeres,
resulting in a null cMyBP-C sarcomere [21] and non-transgenic
FvB/N wild-type (WT) mice were used. The (t/t) mouse on a
FvB/N background has been previously characterized to study
the functional deficits of cMyBP-C protein in the heart [50–53].
Evidence of cardiac myopathy development can be detected
within six weeks of birth in (t/t) mice, and functional deficits can
be measured at ten weeks of age. C57BL/6J and C57BL/
10ScSn-Dmdmdx/J (mdx) mice were obtained from The Jackson
Laboratory and were housed at Loyola University Chicago [54].
The present animal experiments were specifically approved by
the protocols of the Institutional Animal Care and Use
Committees at Loyola University Chicago (LU #202172, IACUC
2013008) and the University of Vermont College of Medicine
(UVM IACUC #10-019) and followed the guidelines of the
Guide for the Use and Care of Laboratory Animals published
by the National Institutes of Health.
Western Blot Analysis
Detection of slow MyBP-C (sMyBP-C), fast MyBP-C (fMyBP-
C), and cMyBP-C proteins in cardiac and skeletal muscles was
done with 4-20% SDS-PAGE (mini precast protein gels, Bio-
Rad, Hercules, CA) and Western blotting as previously
described [55]. Tissue extracts from left ventricle, soleus, and
EDL were homogenized in urea buffer (50mM Tris-HCL pH 7.5,
4M urea, 1M thiourea, 0.4% CHAPS, 20mM permine and 20
mM DTT). Homogenates were quantified using Quick StartTM
Bradford protein assay (Bio-Rad, Hercules, CA) and ~10µg of
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each sample were visualized with Coomassie Blue stain (0.25g
R-250 Coomassie Brilliant Blue, 125mL isopropanol, 50mL
acetic acid and 375mL water). For Western blots, protein
bands were transferred to nitrocellulose membranes, detected
with Ponceau S staining (0.1% (w/v) in 5% acetic acid (Sigma-
Aldrich, St. Louis, MO), blocked with Western Blocking
Reagent (Roche, Indianapolis, IN) in T-TBS, and probed with
primary polyclonal anti-cMyBP-C2–14 antibody [55], monoclonal
anti-sMyBP-C antibody (Abcam, Cambridge, MA) and
monoclonal anti-fMyBP-C antibody (Sigma-Aldrich, St. Louis,
MO), and then the respective secondary HRP-conjugated
antibody (1:10000). All immunoblotted membranes were
developed with ECL Prime Western blotting detection reagent
(GE Healthcare, Pittsburg, PA) and imaged on ChemiDoc XRS
(Bio-Rad, Hercules, CA).
Histochemistry
For histopathological examinations, the muscles were
removed from deeply anesthetized mice, drained of blood, and
fixed in 10% formalin. The tissue samples were dehydrated
through a graded series of alcohols and laid open before being
embedded in paraffin. Step-serial sections were taken from 3
samples per group (5 µm). Sections were then stained with
hematoxylin-eosin or Masson’s trichrome [55]. The presence of
necrosis, myocyte disarray fibrosis and calcification was
determined by an expert who was blinded to genotype as
previously described [55].
Electron Microscopy
Muscles were initially fixed by vascular perfusion with
glutaraldehyde/paraformaldehyde. Muscles were then
dissected, and fixation resumed. For negative staining,
myofibrils were isolated from fixed muscles by homogenizing in
rigor solution (100 mM NaCl, 3 mM MgCl2, 2 mM EGTA, 1 mM
NaN3, and 5 mM PIPES, pH 7.0), followed by staining with
0.5% ammonium molybdate on a Formvar/carbon-coated grid.
For sectioning, fixed muscles were post-fixed with 1% OsO4 in
0.1M sodium cacodylate, dehydrated in graded alcohol and
then embedded in Epon. Sections (65 nm thick) were cut with a
diamond knife and stained with uranyl acetate and lead citrate.
A-band length, M-line width, and Z-line width were measured
and averaged using ImageJ (National Institutes of Health [NIH];
http://rsbweb.nih.gov/ij/) as described previously [56].
Functional Analysis
After euthanasia, soleus muscles were removed from mice
and placed into Krebs-bicarbonate buffer bubbled with 95%
O2-5% CO2. Platinum omega-shaped clamps were tied to both
ends of the muscle, which was then placed between two hooks
attached to a length controller and a force transducer. The
muscle bath consisted of Krebs-bicarbonate buffer with 2.5 mM
Ca2+ maintained at pH 7.4 and room temperature. Electrical
stimulations of 3 V, 7 ms duration and 0.5 Hz were delivered
through the hooks. Muscles were also subjected to tetanus at
20 Hz during which mechanical stretches of varying velocities
(20, 40, 60 and 100 ML/s) were applied for 100 ms [57]. The
maximal change in force recorded during the stretch was used
as an index of the viscoelastic stiffness of the muscle under
tetanus. Twitch forces were recorded prior to and after the
tetanus activation; fractional loss of twitch force was used to
estimate injury by stretch.
Promoter Analysis
MYBPC1, MYBPC2, and MYBPC3 encode for slow skeletal,
fast skeletal, and cardiac isoforms of MyBP-C, respectively.
The promoter sequences (upstream 4 kb and downstream 1 kb
from the transcription start site) of mouse MYBPC1, MYBPC2,
and MYBPC3 from the UCSC Genome Browser (http://
genome.ucsc.edu) were scanned for significantly enriched
transcription factor binding sites using the Genomatix Software
Suite (http://www.genomatix.de). The p-values were computed
using genome-wide promoters as the background set, with p <
0.05 as the cutoff for significance.
Statistical Analysis
Data were expressed as mean of standard error with data
from minimum of three independent experiments (SigmaPlot
9.0). Statistical analyses were performed between the groups
using the paired or unpaired Student’s t-test. A value of p<0.05
was considered statistically significant.
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